Heart Defect Closure Device Market Report 2025

This Heart Defect Closure Device market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The heart defect closure device market size has grown rapidly in recent years. It will grow from $1.11 billion in 2024 to $1.27 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to growing number of people with congenital heart problems, ageing population, rising health awareness, increasing R&D, and advancements in catheterization techniques.

The heart defect closure device market size is expected to see rapid growth in the next few years. It will grow to $2.17 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing congenital defects, improved diagnostic techniques, rise in adoption of MRI procedures, rise in use of 3d imaging in heart defect closure procedures, and high occurrence of ischemic stroke. Major trends in the forecast period include technological advancements, development of innovative products, development of next-generation heart closure devices, growing detection of PFO closure devices, and need to assess the benefits of PFO closure for the aged population.

The increasing prevalence of congenital heart problems is expected to drive the growth of the heart defect closure device market in the coming years. Congenital heart problems are structural defects in the heart present from birth. The rise in congenital heart issues can be attributed to factors such as genetic predispositions, environmental influences, and maternal health conditions like diabetes, obesity, and exposure to certain medications or infections during pregnancy. Heart defect closure devices provide minimally invasive solutions to treat these conditions by sealing abnormal heart openings, restoring normal blood flow, reducing complications, and enhancing overall cardiac function. For example, in October 2024, an article published in the National Library of Medicine (NLM), a US-based biomedical research organization, reported a sharp increase in the incidence rate of congenital heart disease (CHD) to 5.46% in 2023, up from 1.12% in 2020, 2.36% in 2021, and 3.87% in 2022. As a result, the growing number of individuals with congenital heart problems is driving the expansion of the heart defect closure device market.

Major companies in the heart defect closure device market are developing self-expanding, double-disc occluders to provide minimally invasive solutions for sealing heart defects. These occluders enhance procedural safety, improve patient outcomes by reducing recovery times, and minimize the risk of complications associated with traditional open-heart surgeries. For example, in September 2022, Abbott Laboratories, a US-based medical devices and healthcare company, launched the Amplatzer Talisman PFO Occlusion System in Europe. This device is designed to close a patent foramen ovale (PFO), an abnormal opening between the left and right atria of the heart that can lead to strokes and other complications. The system uses a minimally invasive procedure to deploy a self-expanding, double-disc occluder made of nitinol wire mesh, effectively sealing the PFO and preventing the passage of clots between the atria.

In February 2023, Boston Scientific Corporation, a US-based medical device manufacturer, acquired a 65% stake in Acotec Scientific Holdings Limited for $0.523 billion. This acquisition enhances Boston Scientific Corporation’s position in China and enables the global commercialization of Acotec Scientific Holdings Limited’s products. Acotec Scientific Holdings Limited is a China-based medical device company specializing in the interventional treatment of vascular diseases.

Major players in the heart defect closure device market are Abbott Laboratories, Medtronic, Koninklijke Philips N.V., Boston Scientific Corporation, Terumo Corporation, Edwards Lifesciences, W L Gore and Associates, B. Braun, BIOTRONIK SE & Co. KG, Lepu Medical Technology, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, AtriCure Inc., LifeTech Scientific Corporation, Baylis Medical Company Inc., Biosense Webster Inc., Sahajanand Medical Technologies Limited, Occlutech, Coherex Medical Inc., Cardia Inc., Acrostak Corporation, Vivasure Medical, Transmural Systems Inc., Cormatrix Cardiovascular Inc., and St. Jude Medical LLC.

North America was the largest region in the heart defect closure device market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in heart defect closure device report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the heart defect closure device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A heart defect closure device is a medical instrument designed to close abnormal openings or defects in the heart's structure, particularly in the septum, the wall that separates the heart's chambers. These devices are used to treat specific heart conditions, such as atrial septal defects or patent foramen ovale, by sealing the openings in the heart's wall. They are implanted through minimally invasive procedures, offering an effective and less invasive alternative to open-heart surgery for patients with these defects.

The primary types of heart defect closure devices include atrial septal defect (ASD) closure devices, left atrial appendage (LAA) closure devices, patent foramen ovale (PFO) closure devices, patent ductus arteriosus (PDA) closure devices, and ventricular septal defect (VSD) closure devices. An ASD closure device is specifically designed to seal a hole in the wall between the heart's two upper chambers. These devices are constructed from various materials such as nitinol and stainless steel and can be delivered through transcatheter, surgical, and other delivery methods by hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The heart defect closure device market research report is one of a series of new reports that provides heart defect closure device market statistics, including the heart defect closure device industry global market size, regional shares, competitors with heart defect closure device market share, detailed heart defect closure device market segments, market trends, and opportunities, and any further data you may need to thrive in the heart defect closure device industry. These heart defect closure device market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The heart defect closure device market consists of sales of amplatzer septal occluder, gore cardioform septal occluder, and HELEX septal occluder. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.